HD-OPM Archive
Hashtags

#tghdlratio

16 posts

HDL and ApoA-I raising therapies repeatedly failed, so HDL is probably not directly causal

Mar 11, 2024 · Louis Nervegna ♥ 6 · 💬 9 ↩ 22 LDL, ApoB & lipid panel

Louis reviews why HDL or ApoA-I is probably not causal for heart disease. CETP inhibitor trials failed (ILLUMINATE with torcetrapib was stopped for harm; dal-OUTCOMES with dalcetrapib and ACCELERATE with evacetrapib showed no benefit), as did fibrate and niacin trials and CSL112 infusions, and Mendelian randomization agrees. He proposes HDL and ApoA-I mainly act as a proxy for insulin sensitivity, which is the real causal factor.

High HDL tracks with lower risk in UK Biobank, but HDL-raising drugs have failed

Oct 28, 2026 · Louis Nervegna ♥ 7 · 💬 3 ↩ 1 LDL, ApoB & lipid panel

Louis explains that a viral UK Biobank graph shows higher HDL linked to lower ASCVD risk at any LDL/ApoB, as dozens of earlier observational studies have, though the effect size here is larger. Every randomized HDL-raising drug trial failed on hard outcomes, and Mendelian randomization shows no lifetime benefit from genes raising HDL, so HDL is thought to be a proxy for insulin resistance, which is better measured directly.